Ryvu Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Pawel Przewiezlikowski
Chief executive officer
zł1.1m
Total compensation
| CEO salary percentage | 78.4% |
| CEO tenure | no data |
| CEO ownership | 17.4% |
| Management average tenure | 3.2yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
The Market Lifts Ryvu Therapeutics S.A. (WSE:RVU) Shares 26% But It Can Do More
Dec 07
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?
Jan 25What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?
Feb 05Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return
Dec 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -zł104m |
| Jun 30 2024 | n/a | n/a | -zł96m |
| Mar 31 2024 | n/a | n/a | -zł94m |
| Dec 31 2023 | zł1m | zł838k | -zł92m |
| Sep 30 2023 | n/a | n/a | -zł73m |
| Jun 30 2023 | n/a | n/a | -zł66m |
| Mar 31 2023 | n/a | n/a | -zł75m |
| Dec 31 2022 | zł341k | zł165k | -zł84m |
| Sep 30 2022 | n/a | n/a | -zł94m |
| Jun 30 2022 | n/a | n/a | -zł105m |
| Mar 31 2022 | n/a | n/a | -zł92m |
| Dec 31 2021 | zł1m | n/a | -zł79m |
| Sep 30 2021 | n/a | n/a | -zł72m |
| Jun 30 2021 | n/a | n/a | -zł61m |
| Mar 31 2021 | n/a | n/a | -zł41m |
| Dec 31 2020 | n/a | n/a | -zł32m |
| Sep 30 2020 | n/a | n/a | -zł40m |
| Jun 30 2020 | n/a | n/a | -zł32m |
| Mar 31 2020 | n/a | n/a | -zł41m |
| Dec 31 2019 | zł524k | zł524k | -zł44m |
| Sep 30 2019 | n/a | n/a | -zł53m |
| Jun 30 2019 | n/a | n/a | -zł60m |
| Mar 31 2019 | n/a | n/a | -zł28m |
| Dec 31 2018 | zł476k | zł476k | -zł23m |
| Sep 30 2018 | n/a | n/a | zł2m |
| Jun 30 2018 | n/a | n/a | zł14m |
| Mar 31 2018 | n/a | n/a | zł21m |
| Dec 31 2017 | zł655k | zł655k | zł6m |
Compensation vs Market: Pawel's total compensation ($USD262.18K) is about average for companies of similar size in the Polish market ($USD274.57K).
Compensation vs Earnings: Pawel's compensation has increased whilst the company is unprofitable.
CEO
Pawel Przewiezlikowski
no data
Tenure
zł1,068,120
Compensation
Mr. Pawel Tadeusz Przewiezlikowski, MSc., MBA, serves as the Chief Executive Officer of BioCentrum Sp. z o.o. Mr. Przewiezlikowski serves as a Member of Supervisory Board of SELVITA S.A.Mr. Przewiezlikow...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | zł1.07m | 17.37% PLN 146.6m | |
| Executive VP | 12.9yrs | zł1.43m | 1.16% PLN 9.8m | |
| COO & Member of the Management Board | 4.1yrs | zł1.18m | 0.17% PLN 1.4m | |
| Chief Business Officer & Member of Management Board | 2.3yrs | zł2.22m | 0.25% PLN 2.1m | |
| Chief Medical Officer & Member of Management Board | 2.3yrs | zł2.17m | 0.058% PLN 492.7k | |
| Human Resources Manager | no data | no data | no data |
3.2yrs
Average Tenure
Experienced Management: RVU's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Supervisory Board | 1.5yrs | zł90.15k | no data | |
| Independent Member of the Supervisory Board | no data | zł159.99k | 0.52% PLN 4.4m | |
| Non-Independent Vice Chairman of Supervisory Board | no data | zł157.23k | 0.40% PLN 3.4m | |
| Member of Supervisory Board | 1.5yrs | zł121.27k | no data | |
| Independent Chairman of the Supervisory Board | 13.9yrs | zł159.78k | 0.22% PLN 1.8m | |
| Non-Independent Member of the Supervisory Board | 5.3yrs | zł157.23k | no data | |
| Non-Independent Member of the Supervisory Board | 5.3yrs | zł157.23k | 0.087% PLN 733.7k |
5.3yrs
Average Tenure
64yo
Average Age
Experienced Board: RVU's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 05:01 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ryvu Therapeutics S.A. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Jonas Peciulis | Edison Investment Research |